El-Gamal MI, Oh CH (2010). "Current status of carbapenem antibiotics". Current Topics in Medicinal Chemistry. 10 (18): 1882–97. doi:10.2174/156802610793176639. PMID 20615191. /wiki/Doi_(identifier)
Fujimoto K, Takemoto K, Hatano K, Nakai T, Terashita S, Matsumoto M, et al. (February 2013). "Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals". Antimicrobial Agents and Chemotherapy. 57 (2): 697–707. doi:10.1128/AAC.01051-12. PMC 3553697. PMID 23147735. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553697
Kato K, Shirasaka Y, Kuraoka E, Kikuchi A, Iguchi M, Suzuki H, et al. (October 2010). "Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport". Molecular Pharmaceutics. 7 (5): 1747–56. doi:10.1021/mp100130b. PMID 20735088. /wiki/Doi_(identifier)
Sugita R (June 2013). "Good transfer of tebipenem into middle ear effusion conduces to the favorable clinical outcomes of tebipenem pivoxil in pediatric patients with acute otitis media". Journal of Infection and Chemotherapy. 19 (3): 465–71. doi:10.1007/s10156-012-0513-5. PMID 23393013. S2CID 1228827. /wiki/Doi_(identifier)
Rossi S, ed. (7 August 2014). "Tebipenem Pivoxil". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 6 April 2015. https://www.medicinescomplete.com/mc/martindale/current/20642-e.htm
Hazra S, Xu H, Blanchard JS (June 2014). "Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosis". Biochemistry. 53 (22): 3671–8. doi:10.1021/bi500339j. PMC 4053071. PMID 24846409. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053071